ライフサイエンスコーパス: pancreatic neuroendocrine tumor

1 sk of lymph node metastases in patients with pancreatic neuroendocrine tumors.

2 ould be independent prognostic biomarkers of pancreatic neuroendocrine tumors.

3 n the diagnosis, prognosis, and treatment of pancreatic neuroendocrine tumors.

4 able tool in the diagnosis and management of pancreatic neuroendocrine tumors.

5 er the last year in EUS in the evaluation of pancreatic neuroendocrine tumors.

6 peutic EUS interventions in the treatment of pancreatic neuroendocrine tumors.

7 utility of EUS in the clinical management of pancreatic neuroendocrine tumors.

8 trinomas comprise the majority of functional pancreatic neuroendocrine tumors.

9 future multi-institutional investigations on pancreatic neuroendocrine tumors.

10 iagnosis, imaging, treatment, and staging of pancreatic neuroendocrine tumors.

11 f rhEndostatin in patients with carcinoid or pancreatic neuroendocrine tumors.

12 h metastatic carcinoid, pheochromocytoma, or pancreatic neuroendocrine tumors.

13 From a prospective database of pancreatic neuroendocrine tumors, all patients with live

14 ents were conducted in mantle cell lymphoma, pancreatic neuroendocrine tumors and astrocytomas.

15 stations include renal carcinomas and cysts, pancreatic neuroendocrine tumors and cysts, pheochromocy

16 val among patients with progressive advanced pancreatic neuroendocrine tumors and was associated with

17 g parathyroid neoplasia, pituitary adenomas, pancreatic neuroendocrine tumors, and carcinoids.

18 Prognostic biomarkers for the pancreatic neuroendocrine tumors are needed.

19 Pancreatic neuroendocrine tumors are rare neoplasms ofte

20 Intraductal papillary mucinous neoplasm and pancreatic neuroendocrine tumor biology affect patient o

21 ther targeting IFNgamma and/or TNFalpha into pancreatic neuroendocrine tumors can alleviate immune su

22 itro accumulation experiments with the human pancreatic neuroendocrine tumor cell line BON-1 were per

23 cent information and advancements concerning pancreatic neuroendocrine tumor diagnosis, imaging chara

24 Gastro-entero-pancreatic neuroendocrine tumors (GEPNETs) are increasin

25 One patient with a pancreatic neuroendocrine tumor had a minor response and

26 tatic spread among patients with early-stage pancreatic neuroendocrine tumors has not been well estab

27 y altered in human tumors, including cognate pancreatic neuroendocrine tumors, implying a generality.

28 ided by both cancer cells and macrophages in pancreatic neuroendocrine tumors in humans and mice.

29 -Met is upregulated in lymphatics in or near pancreatic neuroendocrine tumors in RIP-Tag2 transgenic

30 antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two phase 2 studies

31 gnostic significance of specific proteins in pancreatic neuroendocrine tumors including insulinoma.

32 Although rare, a thorough understanding of pancreatic neuroendocrine tumors is essential for all ph

33 Survival in patients with carcinoid and pancreatic neuroendocrine tumors is significantly better

34 Sunitinib has antitumor activity in pancreatic neuroendocrine tumors; its activity against c

35 ting cathepsin B (CtsB) and CtsS in a murine pancreatic neuroendocrine tumor model.

36 ords of patients with carcinoid (n = 84) and pancreatic neuroendocrine tumors (n = 69) managed at our

37 Controversy remains over whether small pancreatic neuroendocrine tumors need to be surgically r

38 PURPOSE No established treatment exists for pancreatic neuroendocrine tumor (NET) progression after

39 ival by 6.4 months in patients with advanced pancreatic neuroendocrine tumors (NET) compared with pla

40 Pancreatic neuroendocrine tumors (NETs) are rare neoplas

41 ced its first TNM staging classification for pancreatic neuroendocrine tumors (NETs) derived from the

42 Patients with inoperable or unresectable pancreatic neuroendocrine tumors (NETs) have limited tre

43 Although pancreatic neuroendocrine tumors (NETs) in von Hippel-Li

44 ntributing to development and maintenance of pancreatic neuroendocrine tumors (NETs), with special re

45 anding of the pathogenesis of gastrinoma and pancreatic neuroendocrine tumors, new prognostic classif

46 Nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs) are often

47 Patients with nonfunctional pancreatic neuroendocrine tumors (NF-PNETs) have poorer

48 udopapillary neoplasms, cystic variations of pancreatic neuroendocrine tumors, pancreatic ductal aden

49 erogeneity modulated by PDGF-DD signaling in pancreatic neuroendocrine tumors (PanNET).

50 rs; however, its specific functions in human pancreatic neuroendocrine tumors (PanNETs) and spontaneo

51 Pancreatic neuroendocrine tumors (PanNETs) are a rare bu

52 Pancreatic neuroendocrine tumors (PanNETs) are a relativ

53 Pancreatic neuroendocrine tumors (PanNETs) are a type of

54 Efforts to model human pancreatic neuroendocrine tumors (PanNETs) in animals ha

55 mutations of these genes are common in human pancreatic neuroendocrine tumors (PanNETs), we examined

56 time to tumor progression was 7.7 months in pancreatic neuroendocrine tumor patients and 10.2 months

57 One-year survival rate was 81.1% in pancreatic neuroendocrine tumor patients and 83.4% in ca

58 rt, phase II study of advanced carcinoid and pancreatic neuroendocrine tumor patients.

59 xysterol 24-hydroxycholesterol (24S-HC) in a pancreatic neuroendocrine tumor (pNET) model commonly us

60 AC), whereas tumor burden was reduced in the pancreatic neuroendocrine tumor (PNET) model, the latter

61 potential prognostic factor in patients with pancreatic neuroendocrine tumor (pNET).

62 L/6 (B6) background develop both noninvasive pancreatic neuroendocrine tumors (PNET) and invasive car

63 Pancreatic neuroendocrine tumors (PNET) have a poorly de

64 Pancreatic neuroendocrine tumors (pNET), also known as i

65 Pancreatic neuroendocrine tumors (pNETs) are a rare and

66 Sporadic pancreatic neuroendocrine tumors (pNETs) are rare and ge

67 Pancreatic neuroendocrine tumors (PNETs) are rare tumors

68 Management of pancreatic neuroendocrine tumors (PNETs) associated with

69 olecule tyrosine inhibitor sunitinib in both pancreatic neuroendocrine tumors (PNETs) in RIP-Tag2 mic

70 Pancreatic neuroendocrine tumors (PNETs) may evolve and

71 Pancreatic neuroendocrine tumors (PNETs), although rare,

72 There are few effective therapies for pancreatic neuroendocrine tumors (PNETs).

73 th tumor grade and liver metastasis in human pancreatic neuroendocrine tumors (PNETs).

74 cRNA) MEG3 is significantly downregulated in pancreatic neuroendocrine tumors (PNETs).

75 served in a highly angiogenic mouse model of pancreatic neuroendocrine tumor RIP-Tag2.

76 sent study, 12 gastrinoma and nonfunctioning pancreatic neuroendocrine tumor specimens were evaluated

77 re examined in RIP-Tag2 transgenic mice with pancreatic neuroendocrine tumors that developed spontane

78 ors) are the most common type of functioning pancreatic neuroendocrine tumors that occur sporadically

79 evaluate the dose-response relationship for pancreatic neuroendocrine tumors treated with PRRT using

80 24 lesions in 24 patients with metastasized pancreatic neuroendocrine tumors treated with repeated c

81 expression of UCH-L1 and alpha-internexin in pancreatic neuroendocrine tumors was significantly assoc

82 linger et al reported 2 female patients with pancreatic neuroendocrine tumors, WDS, and achlorhydria.

83 ad advanced, low-grade or intermediate-grade pancreatic neuroendocrine tumors with radiologic progres